Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iratumumab + Gemcitabine in Relapsed/Refractory Hodgkin's Disease
NCT00284804Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2005
- Primary completion
- May 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iratumumab in Hodgkin lymphoma (HL), sponsored by Bristol Myers Squibb. Started Nov 2005; status: completed.
02
Drugs
iratumumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00284804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00284804.